Journal of Cardiovascular Disease Research

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

ASSESS MIRCROALBUMINURIA IN ISCHEMIC HEART DIEASE EVIDENCED BY ISCHEMIC ABNORMALITIES IN NON-DIABETIC POPULATION

Name full- Krishna Sai Kiran Sakalabaktula
MBBS - Rangaraya Medical College, Kakinada, Andhra Pradesh, India
Dr. Chidurala Rahul, MBBS
Bachelor of Medicine, Bachelor of Surgery,
Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai
Ede Renusri
MBBS - NRI Medical College, Guntur, Andhra Pradesh, India

ABSTRACT

A developing number of individuals are starting to recognize that microalbuminuria, which is a sign of early kidney debilitation, is a significant gamble factor for cardiovascular problems like ischaemic coronary illness (IHD). The motivation behind this meta-examination and extensive writing survey is to decide the predominance of microalbuminuria in non-diabetic patients who have ischaemic peculiarities that are suggestive of coronary illness (CHD) and to assess its prognostic importance. The reason for this study is to decide how much microalbuminuria may act as an indicator for cardiovascular occasions and passing by directing a thorough examination of studies that have explored the connection among microalbuminuria and ischaemic coronary illness in a populace that doesn't have diabetes. The outcomes give light on the conceivable job that microalbuminuria could play as a harmless biomarker for early determination and hazard separation in patients who don't have diabetes and who are associated with having ischaemic coronary illness. These discoveries suggest that clinical practice and future exploration ways could be impacted by these discoveries.

Keywords: *Microalbuminuria, Ischemic Heart Disease, Non-Diabetic Population, Cardiovascular Risk, Biomarkers, Prognostic Value, Meta-Analysis, Systematic Review*

I. INTRODUCTION

In 2008, it was liable for the passings of around 7.3 million individuals, making it one of the main sources of mortality in the globe right now. It is additionally vital to take note of that around 80% of fatalities that happen because of cardiovascular sickness happen in nations with poor and moderate incomes.(1) [1] As per the globe Wellbeing Association, India is liable for one-fifth of these fatalities that happen all around the globe, especially among more youthful individuals. The consequences of the Worldwide Weight of Infection research show that India has a death rate from cardiovascular sickness that is a lot higher than the remainder of the world (235), with 272 fatalities for every 100,000 individuals. Indians are impacted via cardiovascular illnesses a decade sooner than those in western countries.2 [2] When taken related to the critical monetary weight that is forced by the dismalness and demise rates related with coronary illness (CHD), these disturbing numbers uncover the need of early discovery and hazard definition in everyone. Proportions of fundamental irritation, for example, C-receptive protein and lipoprotein related phospholipase A2, as well as signs of subclinical atherosclerotic illness, like intima-media thickness and lower leg brachial file, have been made and assessed to accomplish this goal. Among the biomarkers that have been created and considered are those that action fundamental irritation. In people who have diabetes mellitus (DM), which is connected with a raised gamble for persistent renal disappointment, pee microalbumin has been found as a marker for fundamental atherosclerosis. This disclosure was made after a lot of study was conducted.Microalbuminuria has been portrayed as a pee egg whites creatinine proportion that is in excess of 30 mg/g in an early morning test or a urinary egg whites discharge rate that is more noteworthy than 30 mg/24 hours. [4] This definition has stayed predictable over the years.[5] It is vital to take note of that these cut-off levels have not yet been sufficiently demonstrated in people who don't have diabetes; they were first planned principally for

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

proteinuria in quite a while. As a subclinical disorder sign, urinary microalbumin is situated toward the start of the reach in a fleeting model of biomarker relationship with expanding coronary illness [6]. The nearby relationship among microalbuminuria and coronary conduit infection can be effectively made sense of by the comparable pathogenetic instruments of endothelial brokenness, foundational irritation, and vascular injury. [7] It is sensible to expect that such a relationship ought to exist whether or not or not diabetes is available simultaneously. It comes as a shock, nonetheless, that there is a tiny measure of proof accessible about the connection between pee microalbumin and IHD in people who don't have diabetes in contrast with the individuals who have diabetes. It has been found by the Copenhagen City Heart Study [8] that minimal measure of egg whites that might be discharged in pee each moment (during the evening) to lay out the lower edge level that is connected with an expanded gamble of coronary illness and mortality in everyone is essentially as low as 4.8 micrograms/minute [11]. Showing the sex-and age-changed relative dangers of coronary illness and mortality in view of pee egg whites discharge (UAE) interquartile stretches was the technique that was utilized to lay out the cut-off level. UAE in the higher quartile (4.8 μg/min) improved the gamble of coronary illness and demise overwhelmingly.

Through the joining of multi-layered information, (for example, hereditary, clinical, and sociodemographic data), accuracy medication offers a possible method for streamlining risk expectation. This is achieved by considering individual variations.8. [9] The Accuracy Medication in Diabetes Drive (PMDI) was laid out in 2018 by the American Diabetes Affiliation (ADA) in organization with the European Relationship for the Investigation of Diabetes (EASD). This drive is driven by worldwide forerunners in accuracy diabetes medication, and it was laid out in acknowledgment of the likely worth of accuracy medication in further developing diabetes anticipation and care. To offer help for the second Worldwide Agreement Report on Accuracy Diabetes Medicine10, this efficient survey has been arranged for the American Diabetes Affiliation and the European Relationship for the Investigation of Diabetes (EASD PMDI). Inside the setting of this more complete undertaking, we did an exhaustive survey and meta-investigation that zeroed in on accuracy expectation for cardiovascular illness results. Albeit prior methodical assessments of biomarkers for the expectation of cardiovascular sickness have been completed in everybody [11-25], the accentuation of this examination was on people who were determined to have type 2 diabetes. Our objective was to track down replies to two inquiries: (1) Which creative markers can foresee cardiovascular illness in people who have type 2 diabetes? (2) Does there exist any information to recommend that these markers further develop risk expectation past the thing is at present being finished? Thinking about these contemplations could possibly prompt the improvement of additional effective techniques for diagnosing and anticipating cardiovascular illness in individuals who have type 2 diabetes, which would ultimately bring about better treatment and avoidance of this issue. Consequently, to recognize those biomarkers that have the most encouraging clinical utility for cardiovascular gamble evaluation, we followed a thorough stepwise methodology. This approach incorporated the assessment of the gradual worth of each biomarker past conventional gamble factors (for example with assessment of progress in different measurements like c-measurement and net renaming improvement - NRI). This approach was suggested by the explanation from the American Heart Relationship for the distinguishing proof of novel markers for cardiovascular illness [26]. Taking everything into account, this deliberate survey and meta-examination found four prognostic markers with high prescient handiness, upheld by moderate to high-strength proof. This was achieved by using a tight examination choice strategy. Moreover, three guess factors showed moderate prescient worth, which was upheld by proof of low to direct strength. Then again, six prognostic elements uncovered poor prescient value, with proof levels going from low areas of strength for to. The gamble scores showed a moderate level of segregation when exposed to inner approval, however their presentation was a lot of more regrettable when exposed to outside approval, particularly in companions that were not the same as the underlying populace.

This examination meant to decide if the degrees of microalbumin in pee are prescient of an expanded gamble of coronary illness in people who don't have diabetes, as well as whether there is an association between microalbumin levels in pee and coronary illness in this specific gathering.

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

II. METHODS

A. Data Sources and Search Strategy

The Favored Detailing Things for Deliberate examination and Meta-Examination (PRISMA) rules, which is a structure that is generally recognized for guaranteeing that efficient surveys are directed with strategic thoroughness and receptiveness, were complied to during the time spent doing this review. The PRISMA stream outline (Figure 1) gives a visual clarification of the thorough and express system that was utilized to find, pick, and coordinate examination that satisfied the pre-laid out qualification conditions. This method was used to incorporate the examinations into the survey. Tracking down examinations that researched the connection between coronary illness and microalbuminuria in individuals who didn't have diabetes required doing an exhaustive pursuit of the writing from the very outset of 2024 to June 2024. This search was directed using various web-based data sets, one of which being PubMed. The inquiry technique consolidated Clinical Subject Heading (Cross section) expressions and catchphrases that were connected with microalbuminuria, ischaemic coronary illness, cardiovascular infection, coronary illness, and non-diabetic populaces. This was finished to augment search awareness and particularity. The Boolean administrators "AND" and "NOT" were utilized. ((Microalbuminuria) AND ((ischaemic coronary illness OR cardiovascular infection OR coronary illness) AND (non-diabetics) NOT (diabetics)) was the hunt approach that was utilized. Through the execution of this procedure, it was guaranteed that the consideration of examination was restricted to concentrates on that especially explored the association among microalbuminuria and coronary illness in networks that didn't have diabetes. Research on populaces who had diabetes was rejected. To additionally advance strategic receptiveness and responsibility, the suggested procedure for directing a methodical survey was tentatively enrolled in the PROSPERO data set which is a notable vault of deliberate surveys.

B. Study Selection and Eligibility Criteria

To find research that explored the possible connection between ischaemic coronary illness and microalbuminuria, an exhaustive methodology for choosing studies was utilized. Papers that didn't satisfy the laid out qualification guidelines were excluded from the investigation. First and foremost, copies were taken out from the query items to forestall the aggregation of repetitive information. Following that, the titles and edited compositions of the excess papers were analyzed to decide if they were appropriate for consideration in the audit.

Ischaemic coronary illness without renal sickness was the second measure for incorporation. Case control, cross-sectional, and review companion plans were additionally thought of. Survey papers that showed a connection among microalbuminuria and ischaemic coronary illness were likewise included.

Conditions for avoidance: 2) Articles written in dialects other than English; 3) Case reports, assessments, and letters to editors; and 4) Diabetes cases that are now known.

To decide if the full-text articles of each of the recognized edited compositions that satisfied the qualification basis were appropriate for consideration in the audit, the full-text articles of those digests were checked. This thorough strategy diminishes predisposition and working on the unwavering quality of the discoveries by guaranteeing that main examinations that fit the pre-laid out rules were remembered for the investigation.

C. Data Collection Quality Assessment

To guarantee the precision, dependability, and legitimacy of the information that was assembled, a complete methodology for information assortment and quality evaluation was utilized. To do this, we utilized a bunch of steps.

In the first place, Creator One gathered and coded each of the significant information drawn from the examinations that were remembered for the audit. To guarantee that the information were precise, a subsequent creator looked into the

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

information that was gotten and contrasted it with the examinations that were directed at first. This two-step process guaranteed that the information extraction would be dependable and predictable in the meantime.

Six of the creators got preparing to guarantee that the method was done in a predictable way, which brought about a significantly more prominent improvement in the consistency and precision of the information extraction process. In this way, these authors partook during the time spent information extraction, which remembered working for matches to gather data from every one of the examinations. Besides the fact that this framework worked on the proficiency of the interaction, however it additionally diminished the fluctuation that existed among analysts.

Every one of the creators partook in the conversations that were held over video gathering to stay away from any potential predispositions and guarantee that the information extraction process was reliable. The vulnerabilities were all settled, any irregularities were accommodated, and the creators had the option to guarantee that the method for information extraction was steady all through the examinations as a whole.

To survey the nature of each exploration as well as the potential for predisposition, the Gamble of Predisposition in Methodical Audits (ROBIS) apparatus was utilized. An extensive methodology is given by this instrument to assessing the potential for predisposition in deliberate surveys. This system thinks about various variables, like the plan of the exploration, its exhibition, its determination, its whittling down, its identification, and its detailing of predispositions. By utilizing the ROBIS strategy, we had the option to survey the degree of systemic quality in every preliminary as well as evaluate how much predisposition that was available. Our capacity to introduce a union of the proof that was more exact and trustworthy was made practical subsequently.

D. Statistical Analysis

Every single factual examination was completed with the help of R Studio, which is an exceptionally compelling instrument for information perception and measurable calculation. The pooled impact size was determined by utilizing multi-changed relative dangers (RR) alongside certainty stretches (CIs) of 95% from every one of the examinations that were remembered for the investigation. A p-worth of under 0.05 demonstrated that the outcomes were measurably huge. Using an irregular impacts model, otherwise called the DerSimonian and Laird approach, it was doable to consider the chance of heterogeneity among the investigations. We used the I2 measurement and the Cochran's Q test to decide the level of heterogeneity in the information. A p-worth of under 0.10 showed that there was a lot of heterogeneity, while an I2 worth of over half recommended that there was a lot of heterogeneity. Subgroup examinations were done to additionally investigate potential reasons for inclination and fluctuation. These investigations were chosen in view of the example size, attributes of the populace, and the length of the subsequent period. A responsiveness examination was completed by involving a pass on one-out strategy to assess the heartiness of the all out impact size. This examination was completed by deliberately erasing each concentrate to research the effect that each study had on the general discoveries.

Table 1: Study includes

Author and Year	Country	Sample size	Median/mean age	Statistical procedure	Definition of microalbuminuria	Summary of study
Ahmed SF et al ; 2022	India	35	52.38 ± 8.52	Cross sectional study	>30mg/24 hours	This study says that in non diabetic cases , urine microalbuminuria seems to be a good marker for predicting the risk of ischemic heart disease

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

Hafsa F et al ; 2020	Pakistan	325	49.9 ± 5.55	Cross sectional study	30-300mg/24 hours	The study found that patients over 60 years are suggested with type 1 or 2 diabetes who develop microalbuminuria be screened for silent myocardial ischemia
Naha S et al ; 2015	India	100	54.98 ± 11.2(cases) ; 54.86 ± 11.5	Case control study	>30mg/24 hours	The study found elevated urine microalbumin is strong and independent association with ischemic heart disease
Jha PK et al ; 2017	India	90	53 ± 3.25 ; 54 ± 2.75	Cross sectional study	30-300mg/24 hours	High microalbuminuria in non-diabetic patients has shown more extensive and somolex angiographic CAD compared to those without microalbuminuria
Nonterah EA et al ; 2022	Africa	9010	50 ± 6	Cross sectional study	>20mg/L	The presence of spot urine albumin may indicate carotid atherosclerosis and high 10 year ASCVD risk in middle aged individuals.
Reddy PP et al ; 2021	India	62	59 ± 12.8	Observational study	20-200mg/L	This study found microalbuminuria to be important screening for the detection and prevention of CVD.

III. RESULTS

A. Literature Search Results

The PRISMA stream graph incorporates an outline of the screening system as well as individuals that were avoided from the review. Through data set looking, the hunt approach created a sum of 100 records; nonetheless, 44 of the investigations were wiped out in light of the fact that they were copies. At the point when it came to article sorts, 25 of the 56 records that were checked were excluded (full-text articles were precluded, alongside the reasons). Of the 31 exploration that were incorporated into the subjective blend, seven of those reviews were accordingly integrated into the quantitative combination, as should be visible in Figure.

There were six examinations that were distributed on the association among microalbuminuria and ischaemic coronary illness in subjects who didn't have diabetes. These examinations were done in the accompanying nations: India, Pakistan, and Africa. Among these examinations, four were cross-sectional investigations, one was a case control study, and one was an observational exploration. These examinations were led in the US. Altogether, there were somewhere in the range

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

of 35 and 9010 individuals remembered for the example. Two of the investigations consider microalbuminuria to be in excess of 20 mg/L, though four of the examinations consider the meaning of microalbuminuria to be more prominent than 30 mg/24 hours. In view of the discoveries of a cross-sectional exploration that was completed in India in 2022, it was viewed that pee microalbuminuria appears to be as a compelling symptomatic for foreseeing the gamble of ischaemic coronary illness in cases that do exclude diabetes. As per the discoveries of the exploration completed in Pakistan in the year 2020, it is suggested that individuals beyond sixty 1 years old have type 1 or type 2 diabetes and who create microalbuminuria be assessed for quiet myocardial ischaemia. A more elevated level of microalbumin in the pee was displayed to have a significant and free association with ischaemic coronary illness, as per an examination that was completed in India in the year 2015. As per the discoveries of one more examination that was done in India in 2017, patients who didn't have diabetes and had high microalbuminuria had greater and somolex angiographic coronary conduit illness (computer aided design) than patients who didn't have microalbuminuria. As per the discoveries of an examination that was completed in Africa, the presence of spot pee egg whites might be demonstrative of carotid atherosclerosis and a high gamble of ASCVD over a time of a decade in people who are moderately aged. Not entirely settled to be a critical evaluating for the distinguishing proof and counteraction of cardiovascular sickness in the examination that was done in India in the year 2021.



Figure 1: Selection of studies to be included for evaluating the associations of biomarkers, genetic markers and non-genetic risk

B. CVD outcomes

In the preliminaries that were inspected, there was an extensive variety of variety in the results of cardiovascular sickness. A middle time of follow-up of five years was recorded across the examinations in general, with an interquartile scope of 3.1 to 7.8 years. Whether they were accounted for alone or in blend, coronary illness, cardiovascular demise, and stroke were the results that were accounted for the third most frequently. The extraordinary greater part of examination (87%) had an obviously characterized result in view of ICD-10 codes, clinical documentation, or settlement. Nine percent of the investigations depended on library or record linkage, while four percent of the examinations either utilized patient self-

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

report or had a dubious definition. Essential counteraction is characterized as the expectation of cardiovascular illness in people who have never been determined to have the sickness, optional counteraction is characterized as the forecast of repetitive cardiovascular infection occasions or movement of cardiovascular sickness in people who have proactively been determined to have the sickness, and blended populaces are characterized as a mix of essential and auxiliary avoidance.

C. Biomarkers

321 (77.2%) of the 416 investigations that were considered were investigations of non-hereditary biomarkers, 48 (11.5%) of the examinations were investigations of hereditary biomarkers, and 47 (11.2%) of the examinations were investigations of non-hereditary gamble scores. Seventy examinations, or 21.8%, of the 321 exploration that researched non-hereditary biomarkers analyzed perceived cardiovascular infection risk factors and were accordingly taken out. Then again, thirty investigations, or 9.3%, were incorporated on the grounds that they utilized an exceptional strategy (for instance, inconstancy, setting) for a laid out risk factor. The excess 218 investigations, which included 195 different biomarkers, were eliminated from the examination since they didn't consider any of the gamble factors related with cardiovascular infection (CVD). In light of a net positive number of studies, 134 of these 195 biomarkers that were examined shown a huge changed connection for foreseeing cardiovascular sickness (CVD). This is a 64 percent increment over the past number of biomarkers. Out of these, 12 (9%) showed improvement in c-measurement, NRI, or IDI in more than one review: N-terminal ace b-type natriuretic peptide (NT-proBNP), C-receptive protein (CRP), troponin T (dynamite), coronary supply route calcium score (CACS), coronary figured tomography angiography (CCTA), single-photon discharge processed tomography (SPECT) scintigraphy, beat wave speed (PWV), galectin-3 (Lady 3), troponin I (TnI), carotid plaque, development separation factor-15 (GDF-15), and triglyceridеglucose (TyG) record. SPECT, TnI, TyG, 25-hydroxyvitamin D, poly (ADP-ribose) polymerase (PARP), and interleukin-6 (IL-6) were the biomarkers that showed expectation execution; in any case, this particular exploration was the only one wherein they were assessed.

NT-proBNP, dynamite, and CCTA were the biomarkers that gave acceptable outcomes to every one of the three expectation execution estimates in more than one examination. The discoveries of these examinations are summed up in Table 1. For NT-proBNP, there were five examinations that found an improvement in c-measurements going from 0.01 to 0.07, a significant ascent in NRI going from 0.04 to 0.50, and a huge rIDI going from 0.012 to 0.48 (in four of the examinations). For dynamite, three examinations found upgrades in c-measurements going from 0.02 to 0.10, significant NRI going from 0.150 to 0.44, and rIDI going from 0.03 to 0.05. These discoveries depended on research led by specialists. Among the exploration that were led on CCTA, three examinations uncovered an improvement in c-measurements that went from 0.08 to 0.35. Moreover, one review tracked down genuinely huge upgrades in NRI of 0.55 and rIDI of 0.046. Based on the size of these signs, NT-proBNP showed the main extra prescient worth among these three biomarkers. Definite data on the level of fluctuation in estimation strategies utilized for every one of these biomarkers.

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025



Figure 2: The gender distribution of the authors of the included studies, as well as the global distribution of origin and ancestry of the research populations, as well as the countries of affiliation, are all provided. Panel A presents the top twenty countries of origin and ancestry of the research populations that were analysed with regard to the studies that were included. The gender distribution of the authors of the included research is shown in Panel B, which also includes the top 20 countries of affiliation. Through the use of human curation and the use of text mining techniques built with R software version 4.1.2, the data that was utilised for this visualisation was gathered from PubMed and PubMed Central [48].

D. Risk scores/models

77 exploration announced the discoveries of 27 unique cardiovascular illness risk scores. Also, the c-measurements got from the interior and outside approval studies, individually. There was just a moderate measure of separation on both the inner and outside approval. Most of hazard scores were made in the US of America, Europe, and East Asia, and 61.1% of the examinations that were utilized for inside approval were considered to have a high gamble by virtue of predisposition. There was a general pattern towards a decrease in model execution when it was approved in countries that were unique in relation to the improvement companion. For example, the FDS research got high c-measurements (>0.80) when it was approved in an Australian partner, yet it accomplished lower c-insights (0.58-0.69) when it was assessed in European countries. During the outside approval process, segregation for the UKPDS and FRS was commonly feeble, which is reliable with the discoveries of earlier examinations [5-7]. Most of expectation models are focused on benchmark

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

boundaries, and hence don't think about time-shifting factors that might change the gamble of cardiovascular sickness (for instance, statins, SGLT-2i, and GLP-1 RA). A prominent special case was the Bravo risk motor, which was delivered in the year 2020 and approved in clinical examinations including patients who were getting SGLT-2i. These preliminaries showed that this hazard motor precisely anticipated cardiovascular medical advantages by exhibiting upgrades in like manner clinical boundaries like A1C, SBP, and BMI. The c-measurements that were amassed from the outside approval concentrates on the gamble scores that had the option to be investigated were as per the following: ADVANCE, CHS, CVD-EDIC, NDR, New Zealand DCS, and UKPDS risk scores. There was just a little level of separation across all of the gamble scores (pooled c-insights going from 0.63 to 0.68), and nobody risk score fundamentally outflanked the others.

E. Sensitivity analyses

Supplemental Figures 16-18 give the discoveries of responsiveness examinations that rejected investigations that represented a high gamble of predisposition from meta-examinations of biomarkers, hereditary gamble score, and hazard scores when pooled examinations were free, separately. These discoveries were gotten by eliminating studies due to their high gamble of inclination. Set up. The consequences of studies that assessed the most encouraging biomarkers and hereditary markers/scores for accuracy expectation of cardiovascular sickness in type 2 diabetes are summed up in Table 2. Moreover, our decisions about the prescient worth and strength of proof for these biomarkers and scores are incorporated all through the table. We thought about the discoveries from the awareness examinations that were talked about in the previous section while we were assembling our union of the proof. NTproBNP (high-proof), dynamite (moderate-proof), TyG (high-proof), and GRS-CHD (moderate-proof) were displayed to have the best prescient handiness, as per the discoveries. The CCTA (low-proof), SPECT scintigraphy (low-proof), and PWV (moderate-proof) prognostic factors were the ones that had a moderate prescient convenience. Various prognostic factors, like CRP (moderate-proof), CACS (low-proof), Lady 3 (low-proof), TnI (low-proof), carotid plaque (low-proof), and GDF-15 (low-proof), were displayed to have a poor prescient value. A quality assessment was performed on the examinations that incorporated the biomarker, the hereditary marker, and the gamble score, individually.

Table 2 a: N-terminal pro B-type natriuretic peptide (NT-proBNP)

First author	Year	Study population	DM pop N	Event N	Outcome	No. of covariates	Risk of Bias	Per unit increase	Hazard ratio (95% CI)
vonSchoben	2015	Primary	200	40	3p MACE, HF	10	Medium	per 1 SD of the logarithms (pg/mL)	1.09 (1.03, 1.15)
Colombo	2017	Mixed	1089	54	CHD, Stroke	13	Low	per 1 SD (pg/mL)	1.19 (1.02, 1.40)
McMurray	2014	Primary	1635	110	3p MACE, HF	13	Low	per 1 SD of the logarithms (pg/mL)	1.09 (1.05, 1.13)
Bruno	2010	Mixed	4825	176	CVM	13	Low	per 1 SD (pg/mL)	1.30 (1.15, 1.46)

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

Bruno	2014	Mixed	5026	259	CHD	13	Low	per 1 SD (pg/mL)	1.32 (1.15, 2.22)
McMurray	2014	Mixed	12434	1049	CHD, CVM, HF, PAD, ACM	11	Medium	per 1 SD of the logarithms (pg/mL)	1.17 (1.10, 1.27)
Sciacica	2020	Primary	NR	30	CHD, Stroke	14	High	per 1 logarithm (pg/mL)	1.98 (1.56, 2.55)
Savonitto	2016	Secondary	7226	201	CVM	14	Low	per 1 logarithm (pg/mL)	1.50 (1.24, 1.79)
Roth	2019	Secondary	3127	65	CHD, CVM, HF, ACM	10	High	per 1 logarithm (pg/mL)	1.53 (1.08, 2.17)
Lorenzo-Almoros	2020	Secondary	232	56	CHD, Stroke	15	Medium	per 1 logarithm (pg/mL)	0.95 (0.88, 1.03)
Sharma	2020	Secondary	5330	837	3p MACE, HF	14	Medium	per 1 logarithm to base 2 (pg/mL)	1.24 (1.18, 1.31)



Figure 3 (a): N-terminal

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

Panel b: Troponin T (TnT)

First author	Year	Study population	DM pop N	Event N	Outcome	No. of covariates	Risk of Bias	Per unit increase / Cutoff for biomarker	Hazard ratio (95% CI)
McMurray	2011	Mixed	4038	1010	3p MACE, HF	29	Low	>0.028 ng/mL vs. ≤0.028 ng/mL	1.50 (1.06, 2.13)
Keller	2018	Mixed	1040	377	3p MACE	17	Low	Q4 (≥0.09 ng/mL) vs. Q1 (≤0.03 ng/mL)	2.12 (1.62, 2.77)
Resl	2016	Mixed	746	171	CHD, Stroke, HF, PAD, ACM	10	Low	per 1 logarithm (pg/mL)	1.43 (1.13, 1.81)
Sirtica	2016	Mixed	1230	341	3p MACE, HF	15	High	per 1 SD of the logarithms (pg/mL)	1.41 (1.25, 1.59)
Everett	2015	Secondary	1984	198	CHD, MACE, ACM	18	Low	≥14 ng/L vs. <14 ng/L	2.05 (1.22, 1.99)
Lepojärvi	2017	Secondary	1038	37	CHD, CVM, HF	11	Low	≥14 ng/L vs. <14 ng/L	15.55 (6.90, 27.91)
Roth	2019	Secondary	759	NR	CHD, CVM, HF, ACM	13	Low	≥14 ng/L vs. <14 ng/L	1.91 (1.45, 2.51)
Lorenzo-Almoros	2020	Secondary	232	NR	CHD, Stroke	15	Low	per 1 SD (pg/mL)	1.02 (0.84, 1.23)

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025



(b): Troponin T (TnT)

Panel c: Coronary computed tomography angiography (CCTA)

First author	Year	Study population	DM pop N	Event N	Outcome	No. of covariates	Risk of Bias	Per unit increase / Cutoff for biomarker	Hazard ratio (95% CI)
Lee	2017	Primary	933	94	CHD, Revasc, ACM	7	Medium	obstructive CAD ≥50% vs. ≤50%	3.83 (2.45, 5.98)
Halon	2019	Mixed	630	24	CHD	3	High	mild/plaque calcification <50% vs. other	2.50 (1.67, 3.74)
Halon	2016	Primary	254	64	CHD, CVM, Angina	9	High	per 1 quartile of Geninsis score	7.79 (1.75, 34.70)
Tian	2019	Mixed	164	20	CHD, CVM, Angina	9	Medium	obstructive CAD vs. no CAD	9.00 (2.45, 5.98)

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025



(c): Coronary computed tomography angiography (CCTA)

IV. DISCUSSION

Our exhaustive examination of prognostic markers for cardiovascular illness in individuals with type 2 diabetes has uncovered various critical discoveries. To start, just few the various examinations that have been directed to research the prognostic meaning of cardiovascular sickness risk markers have reliably observed that a couple of them are fundamentally connected with cardiovascular gamble generally speaking. It ought to be noticed that NT-proBNP, dynamite, TyG, and GRS-CHD were the ones that showed the most elevated prescient utility, with NT-proBNP having the most undeniable proof. Nonetheless, most of the leftover markers have not been exposed to adequate testing or contrasted with the laid out risk factors for cardiovascular illness. All in all, regardless of the way that specific markers have shown that they are fit for anticipating cardiovascular occasions past what the current gamble factor-based models can give, their application in clinical practice is as yet restricted. This is on the grounds that there is inadequate proof of their contemporary clinical utility.

Throughout the hunt cycle, it was found that countless examinations didn't meet the rules important to be remembered for our methodical survey. Most of the examinations that were accessible were of a cross-sectional plan, and just few them focused explicitly on individuals who had type 2 diabetes and researched the early utility of chance elements and biomarkers in foreseeing future cardiovascular occasions. One of the main impediments of many investigations was that they didn't sufficiently adapt to laid out cardiovascular infection risk factors. In any event, when studies considered changes, just a little part of them assessed clinical utility past the utilization of laid out risk factors. This finding features the need of directing examinations that are better planned to work on how we might interpret the prognostic worth of markers for cardiovascular sickness in type 2 diabetes. Most of the investigations that were integrated into the last examination were completed on people who were of European, East Asian, or South Asian family. The US of America, the Unified Realm, China, Japan, and Italy were the best five nations of enrollment. There was an absence of portrayal of

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

African nations and lineage. At the point when it came to the nations of creator connection, it was likewise certain that there was a slanted geological dissemination, with similar top five nations overwhelming the volume of distributions. Disregarding the way that the geological and tribal irregularity that was accounted for here for biomarker studies isn't however articulated as what seemed to be as of late announced for GWAS studies448, it features the critical need to further develop information assortment, biomarker disclosure and approval, as well as the improvement of populace explicit cardiovascular gamble expectation models in under-addressed populaces and family lines with expectations of aiding the decrease of medical services disparities449. The novel biomarker that arose as the best indicator in our examinations was NT-proBNP. As a matter of fact, it fulfilled each of the rules of prescient and clinical utility, as confirmed by the way that different examinations showed an improvement in all forecast execution pointers, and the consequences of these examinations and meta-examinations were reliable with each other.

Critically, it was found that this biomarker could likewise be used as a prognostic marker for cardiovascular illness that had happened in everyone. The consequences of our review show that NT-proBNP, notwithstanding its notable capability in the finding and treatment of patients who are experiencing cardiovascular breakdown, could likewise be used as a marker for the expectation of cardiovascular sickness. High awareness CRP, otherwise called hs-CRP, is one more biomarker that has been found in everyone that can work on the forecast of essential cardiovascular sickness risk among asymptomatic moderately aged grown-ups. CRP was found to have a low prescient utility with a moderate strength of proof, as per our survey. This could be because of the way that there is a level of fluctuation in the shorts that are utilized for this marker, the moderately modest number of review, the way that diabetes makes various impacts, or the way that it is less delicate to recognize second rate vascular irritation (in contrast with hs-CRP).

V. CONCLUSION

This piece of work benefits from various particular benefits. This offers, apparently, one of the most exhaustive outlines of the ongoing degree of data about the gamble delineation of cardiovascular results in type 2 diabetes. We utilized research that were led after the year 1990 to integrate both more seasoned investigations and later examinations into our examination. By utilizing "biomarkers" in its greatest sense, we had the option to introduce a fair survey of the numerous procedures that are at present being explored to further develop risk categorisation. Our capacity to focus on research that could add to guess was made conceivable by confining the examination to those that utilized longitudinal accomplices. At the point when we limited our examinations to "hard" cardiovascular endpoints, as opposed to likewise incorporate proxy endpoints such carotid intima-average thickness, we had the option to focus on endpoints that would have the most noteworthy restorative importance. Nonetheless, in spite of the way that this strategy empowers us to capitalize on the translational way to deal with our examinations, it is conceivable that future exploration that focusses on the distinguishing proof of biomarkers related with early sickness enlightening endpoints (for instance, subclinical markers of atherosclerosis or minor cardiovascular illness) could uncover an assortment of novel biomarkers for beginning phase cardiovascular complexities. In our examination, there are sure limitations. We had to leave out a critical number of cross-sectional exploration since the methodical survey covered such a wide scope of points and the accentuation that was put on longitudinal investigations was made sense of. Distributions written in English were the only ones we considered. It is conceivable that the quantity of hereditary examinations that were found was decreased because of our hunt standards, which were perhaps more delicate to distinguishing research on clinical gamble elements and biomarkers than they were to recognizing hereditary factors. By and by, we had the option to upgrade this by reintegrating specific lost pieces by utilizing the perceived writing and the experience of the specialists that directed the examination. All in all, our far reaching evaluation of prognostic pointers for cardiovascular endpoints in type 2 diabetes has uncovered various disclosures that, as far as we could possibly know, have not been distributed before. Moreover, it has exposed various critical information holes. We found that NT-proBNP, dynamite, TyG, and GRS-CHD all displayed huge prescient convenience past the laid out risk factors for cardiovascular infection (CVD), with NT-proBNP having the most grounded

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

proof, as per our discoveries. There was just sufficient proof for the polygenic gamble score for coronary illness (CHD) among the hereditary markers, and the prescient worth of hazard scores was on the lower end of the range when it came to outer approval. Given the generally modest number of studies that have been led to examine these new prognostic pointers utilizing a thorough procedure, our outcomes give trustworthiness to the idea that more examination ought to be led to assess these markers and give enticing proof of their steady prescient pertinence. It appears to be that NT-proBNP is the just biomarker that is fit to be analyzed tentatively to evaluate its handiness in changing clinical practice to anticipate the gamble of cardiovascular sickness.

REFERENCES

[1]. Alwan A, Maclean DR, Riley LM, d'Espaignet ET, Mathers CD, Stevens GA, et al. Monitoring and surveillance of chronic non-communicable diseases: Progress and capacity in high-burden countries. Lancet. 2010;376:1861–8. [PubMed] [Google Scholar] [Ref list]

[2]. Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India. Circulation. 2016; 133:1605e1620.

[3]. Koenig W. Cardiovascular biomarkers: Added value with an integrated approach? Circulation. 2007;116:3–5. [PubMed] [Google Scholar] [Ref list]

[4]. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356–60.

[5]. American Diabetes Association. Standards of medical care in diabetes—2006. Diabetes Care. 2006;29(Suppl 1):S4–42. [PubMed] [Google Scholar] [Ref list]

[6]. Vasan RS. Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation. 2006;113:2335–62. [PubMed] [Google Scholar] [Ref list]

[7]. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2:581–90. [PubMed] [Google Scholar] [Ref list]

[8]. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M. The Copenhagen City Heart Study. Eur Heart J Suppl 2001; 3 (Suppl. 8): H1–83.

[9]. Rawshani, A. et al. Mortality and cardiovascular disease in Type 1 and Type 2 diabetes. Nw Eng. J. Med. 376, 1407–1418 (2017).

[10]. Pearson-Stuttard, J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrin. 9, 165–173 (2021).

[11]. Nathan, D. M. et al. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 387, 1063–1074 (2022).

[12]. D. F. Diabetes Atlas. Diabetes around the world in 2021, https://diabetesatlas. org/ (2021).

[13]. van Dieren, S. et al. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with Type 2 diabetes. Diabetologia 54, 264–270 (2011).

[14]. Szymonifka, J. et al. Cardiovascular disease risk prediction for people with type 2 diabetes in a population-based cohort and in electronic health record data. JAMIA Open 3, 583–592 (2020).

[15]. Ho, J. C. et al. Evaluation of available risk scores to predict multiple cardiovascular complications for patients with type 2 diabetes mellitus using electronic health records. Comp. Methods Prog. Biomed. Update 3, 100087 (2023).

[16]. Chung, W. K. et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes Care 43, 1617–1635 (2020).

[17]. Nolan, J. J. et al. ADA/EASD precision medicine in diabetes initiative: an international perspective and future vision for precision medicine in diabetes. Diabetes Care 45, 261–266 (2022).

[18]. Tobias, D. K. et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat. Med. 29, 2438–2457 (2023).

[19]. Damen, J. A. et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ 353, i2416 (2016).

[20]. Zhiting, G. et al. Cardiovascular disease risk prediction models in the Chinese population- a systematic review and meta-analysis. BMC Public Health 22, 1608 (2022).

[21]. Damen, J. A. et al. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med. 17, 109 (2019).
[22]. Romero-Cabrera, J. L., Ankeny, J., Fernández-Montero, A., Kales, S. N. & Smith, D. L. A systematic review and meta-analysis of advanced biomarkers for predicting incident cardiovascular disease among asymptomatic middle- aged adults. Int. J. Mol. Sci. 23, 13540 (2022).
[23]. van Holten, T. C. et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta- analyses. PLoS One 8, e62080 (2013).
[24]. Guasti, L. et al. TMAO as a biomarker of cardiovascular events: a systematic review and meta-analysis. Intern. Emerg. Med. 16, 201–207 (2021).
[25]. Rienks, J., Barbaresko, J. & Nöthlings, U. Association of polyphenol biomarkers with cardiovascular disease and mortality risk: a systematic review and meta-analysis of observational studies. Nutrients 9, 415 (2017).
[26]. Gohel, V., Jones, J. A. & Wehler, C. J. Salivary biomarkers and cardiovascular disease: a systematic review. Clin. Chem. Lab Med. 56, 1432–1442 (2018).
[27]. Kanbay, M. et al. Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int. Urol. Nephrol. 48, 2029–2042 (2016).
[28]. Heianza, Y., Ma, W., Manson, J. E., Rexrode, K. M. & Qi, L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. J. Am. Heart Assoc. 6, e004947 (2017).
[29]. Wallace, T. C., Slavin, M. & Frankenfeld, C. L. Systematic review of anthocyanins and markers of cardiovascular disease. Nutrients 8, 32 (2016).
[30]. Emadian, A., Andrews, R. C., England, C. Y., Wallace, V. & Thompson, J. L. The effect of macronutrients on glycaemic control: a systematic review of dietary randomised controlled trials in overweight and obese adults with type 2 diabetes in which there was no difference in weight loss between treatment groups. Br. J. Nutr. 114, 1656–1666 (2015).
[31]. Yun, H., Noh, N. I. & Lee, E. Y. Genetic risk scores used in cardiovascular disease prediction models: a systematic review. Rev. Cardiovasc. Med. 23, 8 (2022).
[32]. Jeong, E. G. et al. Depth and combined infection is important predictor of lower extremity amputations in hospitalized diabetic foot ulcer patients. Korean J. Intern Med. 33, 952–960 (2018).
[33]. Lin, J. S. et al. Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US preventive services task force. Jama 320, 281–297 (2018).
[34]. Hlatky, M. A. et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119, 2408–2416 (2009).
[35]. Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).
[36]. Wells GA, S. B., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, https://www.ohri.ca/ programs/clinical_epidemiology/oxford.asp.
[37]. Viechtbauer, W. Conducting meta-analyses in R with the metafor Package. J. Stat. Soft. 36, 1–48 (2010).
[38]. Owens, D. K. et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions–agency for healthcare research and quality and the effective health-care program. J. Clin. Epidemiol. 63, 513–523 (2010).
[39]. Aromataris E. et al. JBI Manual for Evidence Synthesis. JBI, https://doi.org/10. 46658/JBIMES-20-01 (2020).
[40]. Aboyans, V. et al. The prognosis of diabetic patients with high ankle-brachial index depends on the coexistence of occlusive peripheral artery disease. J. Vasc. Surg. 53, 984–991 (2011).
[41]. Abu-Lebdeh, H. S., Hodge, D. O. & Nguyen, T. T. Predictors of macrovascular disease in patients with Type 2 diabetes mellitus. Mayo Clin. Proc. 76, 707–712 (2001).
[42]. Afarideh, M. et al. Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in Type 2 diabetes. Atherosclerosis 254, 42–51 (2016).
[43]. Afsharian, S. et al. Risk factors for cardiovascular disease and mortality events in adults with Type 2 diabetes- a 10-year follow-up: Tehran lipid and glucose study. Diabetes Metab. Res. Rev. 32, 596–606 (2016).
[44]. Alele, J. D., Luttrell, L. M., Hollis, B. W., Luttrell, D. K. & Hunt, K. J. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis 228, 502–507 (2013).

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

[45]. Alkhalaf, A. et al. Sex specific association between carnosinase gene CNDP1 and cardiovascular mortality in patients with Type 2 diabetes (ZODIAC-22). J. Nephrol. 28, 201–207 (2015).
[46]. Anand, D. V., Lahiri, A., Lim, E., Hopkins, D. & Corder, R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated Type 2 diabetic subjects. J. Am. Coll. Cardiol. 47, 1850–1857 (2006).
[47]. Anand, D. V. et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur. Heart J. 27, 713–721 (2006).
[48]. Anavekar, N. S. et al. Predictors of cardiovascular events in patients with Type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl, 66 S50-55 (2004).
[49]. Angiolillo, D. J. et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50, 1541–1547 (2007).
[50]. Anyanwagu, U., Donnelly, R. & Idris, I. Albuminuria regression and all-cause mortality among insulin-treated patients with Type 2 Diabetes: analysis of a large UK primary care Cohort. Am. J. Nephrol. 49, 146–155 (2019).
[51]. Apperloo, E. M., Pena, M. J., de Zeeuw, D., Denig, P. & Heerspink, H. J. L. Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with Type 2 diabetes: a primary care cohort study. Diabetes Obes. Metab. 20, 1377–1383 (2018).
[52]. Araki, S. et al. Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 36, 1248–1253 (2013).
[53]. Avogaro, A. et al. Incidence of coronary heart disease in Type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30, 1241–1247 (2007).
[54]. Azab, B., Chainani, V., Shah, N. & McGinn, J. T. Neutrophil-lymphocyte ratio as a predictor of major adverse cardiac events among diabetic population: a 4-year follow-up study. Angiology 64, 456–465 (2013).
[55]. Azevedo, M. J. et al. Value of diagnostic tools for myocardial ischemia used in routine clinical practice to predict cardiac events in patients with type 2 diabetes mellitus: a prospective study. Arq. Bras. Endocrinol. Metab. 50, 46–52 (2006).
[56]. Bacci, S. et al. The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients. Diabetes 60, 1000–1007 (2011).
[57]. Backhaus, S. J. et al. Cardiac magnetic resonance myocardial feature tracking for optimized risk assessment after acute myocardial infarction in patients with Type 2 Diabetes. Diabetes 69, 1540–1548 (2020).
[58]. Basu, S. et al. Validation of risk Equations for complications of Type 2 diabetes (RECODe) using individual participant data from diverse longitudinal Cohorts in the U.S. Diabetes Care 41, 586–595 (2018).
[59]. Basu, S., Sussman, J. B., Berkowitz, S. A., Hayward, R. A. & Yudkin, J. S. Development and validation of risk equations for complications Of Type 2 diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol. 5, 788–798 (2017).
[60]. Bates, R. E. et al. Impact of stress testing for coronary artery disease screening in asymptomatic patients with diabetes mellitus: a community-based study in olmsted county, Minnesota. Mayo Clin. Proc. 91, 1535–1544 (2016).
[61]. Beaney, K. E. et al. Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particles but not with amino acids. Cardiovasc. Diabetol. 15, 115 (2016).
[62]. Beilin, J., Stanton, K. G., McCann, V. J., Knuiman, M. W. & Divitini, M. L. Microalbuminuria in Type 2 diabetes: an independent predictor of cardiovascular mortality. Aust. N Z J. Med. 26, 519–525 (1996).
[63]. Bell, K. J. L. et al. Prognostic impact of systolic blood pressure variability in people with diabetes. PLoS One 13, e0194084 (2018).
[64]. Berkelmans, G. F. N. et al. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500,000 patients with Type 2 diabetes mellitus. Eur Heart J 40, 2899–2906 (2019).
[65]. Bernard, S. et al. Relation between XbA1 apolipoprotein B gene polymorphism and cardiovascular risk in a Type 2 diabetic cohort. Atherosclerosis 175, 177–181 (2004).
[66]. Bernard, S. et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic Type 2 diabetic subjects. Diabetes Care 28, 1158–1162 (2005).

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

[67]. Bianco, H. T. et al. Relevance of target-organ lesions as predictors of mortality in patients with diabetes mellitus. Arq Bras Cardiol 103, 272–281 (2014).
[68]. Biscetti, F. et al. Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study. Cardiovasc. Diabetol. 19, 170 (2020).
[69]. Bonito, B., Silva, A. P., Rato, F., Santos, N. & Neves, P. L. Resistin as a predictor of cardiovascular hospital admissions and renal deterioration in diabetic patients with chronic kidney disease. J. Diabetes Complications 33, 107422 (2019).
[70]. Bosevski, M., Borozanov, V., Tosev, S. & Georgievska-Ismail, L. Is assessment of peripheral endothelial dysfunction useful tool for risk stratification of Type 2 diabetic patients with manifested coronary artery disease? Int. J. Cardiol. 131, 290–292 (2009).
[71]. Bouchi, R. et al. Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with Type 2 diabetes. J. Diabetes Invest. 3, 148–155 (2012).
[72]. Brownrigg, J. R. et al. Microvascular disease and risk of cardiovascular events among individuals with Type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 4, 588–597 (2016).
[73]. Bruce, D. G., Davis, W. A., Starkstein, S. E. & Davis, T. M. A prospective study of depression and mortality in patients with Type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 48, 2532–2539 (2005).
[74]. Bruno, G., Barutta, F., Landi, A., Cavallo Perin, P. & Gruden, G. NT-proBNP linking low-moderately impaired renal function and cardiovascular mortality in diabetic patients: the population-based Casale Monferrato Study. PLoS One 9, e114855 (2014).
[75]. Bruno, G. et al. N-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population- based study. Diabetes Care 36, 2677–2682 (2013).
[76]. Bruno, G. et al. Fibrinogen and AER are major independent predictors of 11- year cardiovascular mortality in Type 2 diabetes: the Casale Monferrato Study. Diabetologia 48, 427–434 (2005).
[77]. Bruno, G. et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in Type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27, 2689–2694 (2004).
[78]. Burgess, D. C. et al. Incidence and predictors of silent myocardial infarction in Type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur. Heart J. 31, 92–99 (2010).
[79]. Busch, M. et al. The advanced glycation end product N(epsilon)- carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am. J. Kidney Dis. 48, 571–579 (2006).
[80]. Böger, C. A. et al. RANTES gene polymorphisms predict all-cause and cardiac mortality in Type 2 diabetes mellitus hemodialysis patients. Atherosclerosis 183, 121–129 (2005).
[81]. Cardona, A. et al. Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis. BMJ Open Diabetes Res Care 7, e000718 (2019).
[82]. Cardoso, C. R., Ferreira, M. T., Leite, N. C. & Salles, G. F. Prognostic impact of aortic stiffness in high-risk Type 2 diabetic patients: the Rio deJaneiro Type 2 Diabetes Cohort Study. Diabetes Care 36, 3772–3778 (2013).
[83]. Cardoso, C. R., Leite, N. C. & Salles, G. F. Prognostic importance of
[84]. C-Reactive protein in high cardiovascular risk patients with Type 2 diabetes mellitus: the Rio de Janeiro Type 2 diabetes Cohort Study. J. Am. Heart Assoc. 5, e004554 (2016).
[85]. Cardoso, C. R., Salles, G. F. & Deccache, W. Prognostic value of QT interval parameters in Type 2 diabetes mellitus: results of a long-term follow-up prospective study. J. Diabetes Complications 17, 169–178 (2003).
[86]. Cardoso, C. R. L., Leite, N. C., Moram, C. B. M. & Salles, G. F. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with Type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc. Diabetol. 17, 33 (2018).
[87]. Cardoso, C. R. L., Leite, N. C. & Salles, G. F. Prognostic importance of visit-to- visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc. Diabetol. 19, 50 (2020).

ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 7, 2025

[88]. Cardoso, C. R. L., Salles, G. C., Leite, N. C. & Salles, G. F. Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro Type 2 diabetes cohort study. Cardiovasc. Diabetol. 18, 2 (2019).

[89]. Carlsson, A. C. et al. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J. Med. Sci. 125, 37–43 (2020).

[90]. Carlsson, A. C. et al. Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in Type 2 diabetes. Cardiovasc. Diabetol. 15, 40 (2016).

[91]. Carnethon, M. R. et al. Association of weight status with mortality in adults with incident diabetes. JAMA 308, 581–590 (2012).

[92]. Casiglia, E. et al. Cardiovascular mortality in non-insulin-dependent diabetes mellitus. A controlled study among 683 diabetics and 683 age- and sex- matched normal subjects. Eur. J. Epidemiol. 16, 677–684 (2000).

[93]. Cavalot, F. et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in Type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care 34, 2237–2243 (2011).

[94]. Cavalot, F. et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in Type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J. Clin. Endocrinol. Metab. 91, 813–819 (2006).

[95]. Cea Soriano, L., Johansson, S., Stefansson, B. & Rodríguez, L. A. Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with Type 2 diabetes: associations with renal function and cardiovascular risk factors. Cardiovasc. Diabetol. 14, 38 (2015).